Letrozole in Stimulated IVF Cycles

PHASE3CompletedINTERVENTIONAL
Enrollment

900

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

April 30, 2022

Study Completion Date

April 30, 2023

Conditions
Subfertility
Interventions
DRUG

Letrozole

Daily 150-300 IU human menopausal gonadotrophin (HMG) / Follicle stimulating hormone (FSH) from cycle day 2-4 (at least 5 days after stopping the oral contraceptive pill) and co-treatment with letrozole 2.5 mg daily from stimulation day 5 until the day before hCG administration. GnRH antagonist (cetrotide or orgalutran) 0.25 mg daily from stimulation day 5 until the day of hCG administration.

Trial Locations (2)

100191

Peking University Third Hospital, Beijing

Unknown

Department of Obstetrics and Gynaecology, Hong Kong

All Listed Sponsors
collaborator

Peking University Third Hospital

OTHER

lead

The University of Hong Kong

OTHER

NCT02912988 - Letrozole in Stimulated IVF Cycles | Biotech Hunter | Biotech Hunter